Table 1.
Clinical trials evaluating anti-TIGIT immunotherapeutics started in 2021 (accessed on March 14, 2022).
| NCT Number | Interventstions/Drug | Conditions | Status | Phases | Start Date |
|---|---|---|---|---|---|
| NCT05251948 | Atezolizumab Capecitabine Oxaliplatin Tiragolumab |
Gastric and gastroesophageal junction carcinoma | Recruiting | Phase 1 Phase 2 |
March 1, 2022 |
| NCT05253105 | TAB006 Toripalimab |
Previously treated, advanced malignancies |
Not yet recruiting | Phase 1 | March 15, 2022 |
| NCT05130177 | Zimberelimab Domvanalimab | Melanoma | Not yet recruiting | Phase 2 | March 2022 |
| NCT05120375 | BAT6021 | Solid tumor | Not yet recruiting | Phase 1 | Not avilable |
| NCT05102214 | HLX301 | Locally advanced or metastatic solid tumors Non-small cell lung cancer |
Recruiting | Phase 2 | January 2022 |
| NCT05073484 | BAT6021 BAT1308 |
Advanced solid tumor | Recruiting | Phase 1 | October 29, 2021 |
| NCT05060432 | EOS-448 Anti-PD1 inupadenant |
Advanced cancer Lung cancer Head and neck cancer Melanoma |
Recruiting | Phase 1 Phase 2 |
September 6, 2021 |
| NCT05061628 | JS006 as Monotherapy JS006 in combination with Toripalimab |
Advanced tumors | Recruiting | Phase 1 | April 21, 2021 |
| NCT05026606 | Etigilimab Nivolumab |
Recurrent fallopian tube clear cell adenocarcinoma Recurrent ovarian clear cell adenocarcinoma Recurrent platinum-resistant fallopian tube carcinoma Recurrent platinum-resistant ovarian carcinoma Recurrent platinum-resistant primary peritoneal carcinoma Recurrent primary peritoneal clear cell adenocarcinoma |
Recruiting | Phase 2 | October 1, 2021 |
| NCT05023109 | GP+PD-1+Tight | Biliary tract carcinoma | Not yet recruiting | Phase 2 | September 1, 2021 |
| NCT05019677 | GP+PD-1+Tight | Intrahepatic cholangiocarcinoma | Not yet recruiting | Phase 2 | September 1, 2021 |
| NCT05014815 | Ociperlimab Tislelizumab histology-based chemotherapy Placebo |
Non-small cell lung cancer | Recruiting | Phase 2 | November 16, 2021 |
| NCT05009069 | Radiotherapy Capecitabine Fluorouracil Atezolizumab Tiragolumab |
Rectal neoplasms Rectal Cancer |
Not yet recruiting | Phase 2 | April 30, 2022 |
| NCT04995523 | AZD2936 | Non-small cell lung carcinoma | Recruiting | Phase 1 Phase 2 |
September 14, 2021 |
| NCT04952597 | Ociperlimab Tislelizumab Concurrent Chemoradiotherapy |
Limited stage small cell lung cancer | Recruiting | Phase 2 | July 15, 2021 |
| NCT04933227 | Atezolizumab Tiragolumab Oxaliplatin Capecitabine |
Stomach neoplasms Gastric cancer Gastroesophageal junction adenocarcinoma |
Recruiting | Phase 2 | August 6, 2021 |
| NCT04866017 | Tislelizumab Durvalumab Chemotherapy Ociperlimab |
Non-small cell lung cancer | Recruiting | Phase 3 | June 17, 2021 |
| NCT04791839 | Zimberelimab Domvanalimab Etrumadenant |
Non-small cell lung cancer Non-small cell carcinoma Non-small cell lung cancer |
Recruiting | Phase 2 | August 4, 2021 |
| NCT04761198 | Etigilimab dosing Nivolumab |
Solid tumor, adult Advanced solid tumor Metastatic solid tumor |
Recruiting | Phase 1 Phase 2 |
March 23, 2021 |
| NCT04746924 | Tislelizumab Ociperlimab Pembrolizumab Placebo |
Non-small cell lung cancer | Recruiting | Phase 3 | June 8, 2021 |
| NCT04736173 | Zimberelimab Domvanalimab Carboplatin Pemetrexed Paclitaxel |
Non-small cell lung cancer Nonsquamous non-small cell lung cancer Squamous non-small cell lung cancer Lung cancer |
Recruiting | Phase 3 | February 1, 2021 |
| NCT04732494 | Tislelizumab Ociperlimab Placebo |
Esophageal squamous cell carcinoma | Recruiting | Phase 2 | March 31, 2021 |
| NCT04693234 | Tislelizumab Ociperlimab |
Cervical cancer | Active, not recruiting | Phase 2 | March 3, 2021 |
| NCT04672356 | IBI939 Sintilimab |
Advanced lung cancer | Recruiting | Phase 1 | January 25, 2021 |
| NCT04656535 | AB122 AB154 Placebo |
Glioblastoma | Recruiting | Early Phase 1 | April 21, 2021 |